Aligos Therapeutics Inc is a publicly traded company operating in the Biotechnology industry. Its shares trade on NASDAQ NMS - GLOBAL MARKET under the ticker ALGS, with a market capitalization of approximately $35 million. A full business summary isn’t available for this company yet — the figures and signals on this pa…
An institutional-grade, numbers-driven thesis on ALGS — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of July 4, 2026, TradersQuant's model rates Aligos Therapeutics Inc (ALGS) 55/100 with a 12-month base-case forecast of $5.49 — -1.8% versus the current price of $5.59. Aligos Therapeutics Inc trades at $5.59 in the Biotechnology sector, with a market capitalisation of $34.6M. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month TradersQuant model price target for ALGS is $5.49, implying -1.8% versus the current price. The model's 12-month scenario range runs from $3.59 (bear) to $8.15 (bull), with a base case of $5.49.
On the fundamentals, Aligos Therapeutics shows trailing revenue of $2.8M, revenue growth of +43.9% YoY. This page also tracks ALGS's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
ALGS currently carries a TradersQuant composite score of 55/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "buy". Our 12-month price target of $5.49 implies -1.8% from $5.59. This is research, not financial advice — always combine it with your own judgement.
The TradersQuant 12-month model price target for ALGS is $5.49, about -1.8% versus the latest price of $5.59. Consensus is based on 13 analysts.
TradersQuant's 12-month model forecast for ALGS is a base case of $5.49, ranging from $3.59 (bear) to $8.15 (bull), an expected return of -1.8%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for ALGS over the next 12 months is $5.49 in the base case (bear $3.59, bull $8.15), versus today's price of $5.59. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for ALGS — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates ALGS's fair value at $7.12, implying +27.4% of expected upside versus the current price.
Aligos Therapeutics does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
